• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by iBio Inc.

    4/5/24 5:11:14 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IBIO alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. _)*

     

    iBio, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    451033708
    (CUSIP Number)
     
    March 26, 2024
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    SCHEDULE 13G

     

    CUSIP No. 451033708

     

    1 Names of reporting persons
    ADAR1 Partners, LP
    2 Check the appropriate box if a member of a group (see instructions)

    (a) ☐

    (b) ☐

    3 SEC use only
     
    4 Citizenship or place of organization
    Delaware

    Number of

    shares

    beneficially

    owned by each

    reporting

    person with:

    5 Sole voting power
    0
    6 Shared voting power
    789,293 (1)
    7 Sole dispositive power
    0
    8 Shared dispositive power
    789,293 (1)

    9 Aggregate amount beneficially owned by each reporting person
    789,293
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ☐
    11 Percent of class represented by amount in Row (9)
    9.27% (2)
    12 Type of reporting person (see instructions)
    PN

     

    (1) Consists of 789,293 shares of common stock of the Issuer, par value $0.001 per share (“Shares”), directly held by ADAR1 Partners, LP as of April 5, 2024.
    (2) Based on 8,515,226 Shares outstanding as of April 1, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2024.

     

    2
     

     

    CUSIP No. 451033708

     

    1 Names of reporting persons
    ADAR1 Capital Management, LLC
    2 Check the appropriate box if a member of a group (see instructions)

    (a) ☐

    (b) ☐

    3 SEC use only
     
    4 Citizenship or place of organization
    Texas

    Number of

    shares

    beneficially

    owned by each

    reporting

    person with:

    5 Sole voting power
    0
    6 Shared voting power
    789,293 (1)
    7 Sole dispositive power
    0
    8 Shared dispositive power
    789,293 (1)

    9 Aggregate amount beneficially owned by each reporting person
    789,293
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ☐
    11 Percent of class represented by amount in Row (9)
    9.27% (2)
    12 Type of reporting person (see instructions)
    OO

     

    (1) Consists of 789,293 shares of common stock of the Issuer, par value $0.001 per share (“Shares”), directly held by ADAR1 Partners, LP as of April 5, 2024. ADAR1 Capital Management, LLC acts as an investment adviser to, and manages investment and trading accounts of, ADAR1 Partners, LP. ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP.
    (2) Based on 8,515,226 Shares outstanding as of April 1, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2024.

     

    3
     

     

    CUSIP No. 451033708

     

    1 Names of reporting persons
    ADAR1 Capital Management GP, LLC
    2 Check the appropriate box if a member of a group (see instructions)

    (a) ☐

    (b) ☐

    3 SEC use only
     
    4 Citizenship or place of organization
    Texas

    Number of

    shares

    beneficially

    owned by each

    reporting

    person with:

    5 Sole voting power
    0
    6 Shared voting power
    789,293 (1)
    7 Sole dispositive power
    0
    8 Shared dispositive power
    789,293 (1)

    9 Aggregate amount beneficially owned by each reporting person
    789,293
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ☐
    11 Percent of class represented by amount in Row (9)
    9.27% (2)
    12 Type of reporting person (see instructions)
    OO

     

    (1) Consists of 789,293 shares of common stock of the Issuer, par value $0.001 per share (“Shares”), directly held by ADAR1 Partners, LP as of April 5, 2024. ADAR1 Capital Management GP, LLC acts as the general partner of ADAR1 Partners, LP. ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP.
    (2) Based on 8,515,226 Shares outstanding as of April 1, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2024.

     

    4
     

     

    CUSIP No. 451033708

     

    1 Names of reporting persons
    Daniel Schneeberger
    2 Check the appropriate box if a member of a group (see instructions)

    (a) ☐

    (b) ☐

    3 SEC use only
     
    4 Citizenship or place of organization
    Switzerland

    Number of

    shares

    beneficially

    owned by each

    reporting

    person with:

    5 Sole voting power
    0
    6 Shared voting power
    789,293 (1)
    7 Sole dispositive power
    0
    8 Shared dispositive power
    789,293 (1)

    9 Aggregate amount beneficially owned by each reporting person
    789,293
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ☐
    11 Percent of class represented by amount in Row (9)
    9.27% (2)
    12 Type of reporting person (see instructions)
    IN

     

    (1) Consists of 789,293 shares of common stock of the Issuer, par value $0.001 per share (“Shares”), directly held by ADAR1 Partners, LP as of April 5, 2024. ADAR1 Capital Management, LLC acts as an investment adviser to, and manages investment and trading accounts of, ADAR1 Partners, LP. ADAR1 Capital Management GP, LLC acts as the general partner of ADAR1 Partners, LP. Mr. Schneeberger is the Manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC. Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP.
    (2) Based on 8,515,226 Shares outstanding as of April 1, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2024.

     

    5
     

     

    Item 1(a) Name of issuer:

     

    iBio, Inc.

     

    Item 1(b) Address of issuer’s principal executive offices:

     

    8800 HSC Parkway, Bryan Texas 77807

     

    Item 2(a) Name of person filing:

     

    This Schedule is being filed on behalf of each of the following persons (each, a “Reporting Person” and collectively, the “Reporting Persons”)

     

      i) ADAR1 Partners, LP (“ADAR1 Fund”);

     

      ii) ADAR1 Capital Management, LLC (“ADAR1 Capital Management”);

     

      iii) ADAR1 Capital Management GP, LLC (“ADAR1 General Partner”); and
         
      iv) Daniel Schneeberger (“Mr. Schneeberger”)

     

    This Schedule relates to shares of common stock of the Issuer, par value $0.001 per share (“Shares”), directly held by ADAR1 Fund. ADAR1 Capital Management acts as an investment adviser to, and manages investment and trading accounts of, ADAR1 Fund. ADAR1 General Partner acts as the general partner of ADAR1 Fund. ADAR1 Capital Management and ADAR1 General Partner may be deemed to indirectly beneficially own securities held by ADAR1 Fund. Mr. Schneeberger is the Manager of ADAR1 Capital Management and ADAR1 General Partner. Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Fund.

     

    Each Reporting Person declares that neither the filing of this Schedule nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act) with any other person as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any syndicate or group with respect to the Issuer or any securities of the Issuer.

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.

     

    Item 2(c) Citizenship:

     

      i) ADAR1 Fund is a Delaware limited partnership;

     

      ii) ADAR1 Capital Management is a Texas limited liability company;

     

      iii) ADAR1 General Partner is a Texas limited liability company; and
         
      iv) Mr. Schneeberger is a citizen of Switzerland.

     

    6
     

     

    Item 2(d) Title of Class of Securities:

     

    Common Stock, par value $0.001 per share

     

    Item 2(e) CUSIP No.:

     

    451033708

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

     

      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

     

      (c) ☐ Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

      (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

      (k) ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________.

     

    7
     

     

    Item 4. Ownership

     

    (a) Amount Beneficially Owned:

     

    As of April 5, 2024, each of the Reporting Persons could have been deemed to be the beneficial owner of 789,293 Shares.

     

    (b) Percent of Class:

     

    As of April 5, 2024, each of the Reporting Persons could have been deemed to be the beneficial owner of approximately 9.27% of the Shares outstanding, based on 8,515,226 Shares outstanding as of April 1, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 1, 2024.

     

    (c) Number of shares as to which such person has:

     

    As of April 5, 2024, for each of the Reporting Persons:

     

      (i) Sole power to vote or to direct the vote: 0

     

      (ii) Shared power to vote or to direct the vote: 789,293

     

      (iii) Sole power to dispose or to direct the disposition of: 0

     

      (iv) Shared power to dispose or to direct the disposition of: 789,293

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    8
     

     

    EXHBIT INDEX

     

    Exhibit       Page No.
    A. Joint Filing Agreement   11

     

    9
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 5, 2024

     

    ADAR1 PARTNERS, LP  
       
    /s/ Daniel Schneeberger  
    Manager of ADAR1 Capital Management GP, LLC, the General Partner of ADAR1 Partners, LP  

     

    ADAR1 CAPITAL MANAGEMENT, LLC  
       
    /s/ Daniel Schneeberger  
    Manager of ADAR1 Capital Management, LLC  

     

    ADAR1 CAPITAL MANAGEMENT GP, LLC  
       
    /s/ Daniel Schneeberger  
    Manager of ADAR1 Capital Management GP, LLC  

     

    DANIEL SCHNEEBERGER  
       
    /s/ Daniel Schneeberger  
       

     

    10
     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    The undersigned hereby agree that the statement on Schedule 13G with respect to the shares of common stock, par value $0.001 per share, of iBio, Inc. dated as of April 5, 2024 is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

    ADAR1 PARTNERS, LP  
       
    /s/ Daniel Schneeberger  
    Manager of ADAR1 Capital Management GP, LLC, the General Partner of ADAR1 Partners, LP  

     

    ADAR1 CAPITAL MANAGEMENT, LLC  
       
    /s/ Daniel Schneeberger  
    Manager of ADAR1 Capital Management, LLC  

     

    ADAR1 CAPITAL MANAGEMENT GP, LLC  
       
    /s/ Daniel Schneeberger  
    Manager of ADAR1 Capital Management GP, LLC  

     

    DANIEL SCHNEEBERGER  
       
    /s/ Daniel Schneeberger  
       

     

    11

     

    Get the next $IBIO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IBIO

    DatePrice TargetRatingAnalyst
    5/28/2024$5.00Buy
    Chardan Capital Markets
    11/29/2021$1.50Mkt Outperform
    JMP Securities
    11/29/2021$1.50Outperform
    JMP Securities
    More analyst ratings

    $IBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on iBio with a new price target

      Chardan Capital Markets initiated coverage of iBio with a rating of Buy and set a new price target of $5.00

      5/28/24 7:42:07 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on iBio with a new price target

      JMP Securities initiated coverage of iBio with a rating of Mkt Outperform and set a new price target of $1.50

      11/29/21 7:34:24 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on iBio with a new price target

      JMP Securities initiated coverage of iBio with a rating of Outperform and set a new price target of $1.50

      11/29/21 7:32:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Legal Officer Banjak Marc

      4 - iBio, Inc. (0001420720) (Issuer)

      2/24/25 6:01:30 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Duran Felipe

      4 - iBio, Inc. (0001420720) (Issuer)

      2/24/25 6:00:59 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Brenner Martin

      4 - iBio, Inc. (0001420720) (Issuer)

      2/24/25 6:00:12 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Duran Felipe bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 472% to 11,139 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:34:37 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Brenner Martin bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 101% to 18,316 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:34:02 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Banjak Marc bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 490% to 11,066 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:33:31 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    SEC Filings

    See more
    • SEC Form 424B3 filed by iBio Inc.

      424B3 - iBio, Inc. (0001420720) (Filer)

      6/24/25 9:00:54 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - iBio, Inc. (0001420720) (Filer)

      6/24/25 7:56:51 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by iBio Inc.

      EFFECT - iBio, Inc. (0001420720) (Filer)

      6/24/25 12:15:21 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

      Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of next-generation antibody therapies, today announced preclinical data in which an engineered amylin receptor agonist antibody reduced acute food intake

      6/24/25 7:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

      Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.Martin Brenner, DVM, Ph.D., iBio's CEO and Chief Scientific Officer, will outline how iBio is pioneering the next generation of antibo

      6/23/25 4:15:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

      iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess early signs of efficacy on fat reduction and body composition Mouse study shows IBIO-610 alone drives an overall body weight loss of 8.9%*, and prevents weight regain following GLP-1 treatment in obese mice, results of which will be presented at ADA on Monday June 23rd SAN DIEGO, June 16, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced the initiation of a NHP study for its Activin E engineered antibody candidate, now

      6/16/25 7:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • iBio to Begin Trading on the Nasdaq Stock Exchange

      SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol "IBIO." The Company's common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025. Martin Brenner, Ph.D., DVM, iBio's CEO and Chief Scientific Officer, commented, "We are pleased to announce our listing on the Nas

      2/19/25 4:05:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Strengthens Board with Appointment of Two New Independent Directors

      SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David Arkowitz and António Parada to its Board of Directors adding key experience in finance, leadership and antibody discovery. "These appointments expand and strengthen our board to align with iBio's vision of becoming a next-generation antibody discovery and development company with a robust clinical pipeline of therapeutic antibodies for cardiometabolic diseases and oncology. As a seasoned CFO, David brings extensive financial experience and industry relationships that will benefit iBio as we

      11/25/24 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Fiscal First Quarter 2025 Financial Results

      SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. "In our fiscal first quarter we advanced our collaboration with AstralBio, manufacturing and dosing a lead molecule with therapeutic potential for muscle wasting and obesity in non-human primate in vivo studies and progressing early work on additional targets. We strengthened our leadership team by hiring a seasoned business development executive, Kristi Sarno—a move essential to our efforts to critically enable new partners in antibody development for challenging targets," said CEO and

      11/12/24 4:05:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by iBio Inc.

      SC 13G - iBio, Inc. (0001420720) (Subject)

      11/14/24 8:47:49 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by iBio Inc.

      SC 13G/A - iBio, Inc. (0001420720) (Subject)

      11/14/24 4:48:52 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by iBio Inc. (Amendment)

      SC 13G/A - iBio, Inc. (0001420720) (Subject)

      4/9/24 5:22:43 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Financials

    Live finance-specific insights

    See more
    • iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

      Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of next-generation antibody therapies, today announced preclinical data in which an engineered amylin receptor agonist antibody reduced acute food intake

      6/24/25 7:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

      Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.Martin Brenner, DVM, Ph.D., iBio's CEO and Chief Scientific Officer, will outline how iBio is pioneering the next generation of antibo

      6/23/25 4:15:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

      – Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets – – Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration – – Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration – BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company") announces today that it has entered into a collaboration agreement with AstralBio,

      3/27/24 7:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care